Jaw bone changes in rats after treatment with zoledronate and pamidronate

Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontology

Volumn 109, Issue 3, 2010, Pages 385-391

  Senel, Figen Cizmeci ^a   Duman, Mine Kadioglu ^a   Muci, Efnan ^a   Cankaya, Mustafa ^a   Pampu, A Alper ^a   Ersoz, Safak ^a   Gunhan, Omer ^b  

^a KARADENIZ TECHNICAL UNIVERSITY   (Turkey)

^b GULHANE SCHOOL OF MEDICINE   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; IMIDAZOLE DERIVATIVE; PAMIDRONIC ACID; ZOLEDRONIC ACID;

ANIMAL; ARTICLE; BONE NECROSIS; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; DISEASE MODEL; DRUG EFFECT; FEMALE; FEMUR; INFLAMMATION; MANDIBLE; PATHOLOGY; RAT; SINGLE BLIND PROCEDURE; SPRAGUE DAWLEY RAT; TIME;

ANIMALS; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; DISEASE MODELS, ANIMAL; FEMALE; FEMUR; IMIDAZOLES; INFLAMMATION; MANDIBLE; OSTEONECROSIS; RATS; RATS, SPRAGUE-DAWLEY; SINGLE-BLIND METHOD; TIME FACTORS;

EID: 77249103471     PISSN: 10792104     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tripleo.2009.10.011     Document Type: Article

References (48)

1. Migliorati C.A., Casiglia J., Epstein J., Jacobsen P., Si{dotless}egel M.A., and Woo S.B. Managing the care of patients with bisphosphonate-associated osteonecrosis. J Am Dent Assoc 136 (2005) 1658-1668
2. Cheng A., Mavrokokki A., Carter G., Stein B., Fazzalari N.L., Wilson D.F., et al. The dental implications of bisphosphonates and bone disease. Aust Dent J 50 4 Suppl 2 (2005) S4-S13
3. Bertoldo F., Santini D., and Lo Cascio V. Bisphosphonates and osteomylelitis of the jaw: a pathogenic puzzle. Nat Clin Pract Oncol 4 (2007) 711-721
4. Dimitrakopoulos I., Magopoulos C., and Karakasis S. Bisphosphonate-induced avascular osteonecrosis of the jaws: a clinical report of 11 cases. Int J Oral Maxillofac Surg 35 (2006) 588-593
5. Senel F.C., Tekin U.S., Bagis B., and Durmus A. Severe osteomyelitis of the mandible associated with the use of non-nitrogen-containing bisphosphonate (Disodium Clodronate): report of a case. J Oral Maxillofac Surg 65 (2007) 562-565
6. Herbozo P.J., Briones D.L., Ferres A.J., and Torrealba L. Severe spontaneous cases of bisphosphonate related osteonecrosis of the jaws. J Oral Maxillofac Surg 65 (2007) 1650-1654
7. Berenson J.R., Hillner B.E., Kyle R.A., Anderson K., Lipton A., Yee G.C., et al. American Society of Clinical Oncology Clinical Practice Guidelines: the role of bisphosphonates in multiple myeloma. J Clin Oncol 20 (2002) 3719-3736
8. Ruggerio S.L., Fantasia J., and Carlson E. Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 102 (2006) 433-439
9. Comprehensive Medical Safety Evaluation Osteonecrosis of the Maxillofacial Area December 2004 Overview. US Food and Drug Administration Oncologic Drugs Advisory Committee meeting briefing document. htpp:// www.fda.gov/ohms/dockets/ac/05/briefing/2005-4095b1.htm
10. American Association of OralMaxillofacial Surgeons. Position paper: bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 65 (2007) 369-376
11. Lam D.K., Sandor G.K.B., Holmes H.I., Evans A.W., and Clokie C.M.L. A review of bisphosphonate-associated osteonecrosis of the jaws and i{dotless}ts management. J Can Dent Assoc 73 (2007) 417-422
12. Melo M.D., and Obeid G. Osteonecrosis of the jaws in patients with a history of receiving bisphosphonate therapy: strategies for prevention and early recognition. J Am Dent Assoc 136 (2005) 1675-1681
13. American Association of OralMaxillofacial Surgeons. Position paper: bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 67 (2009) 2-12
14. In: Marx R.E., and Stern D.S. (Eds). Biopsy principles and techniques. Oral and maxillofacial Pathology: a rationale for diagnosis and treatment (2002), Quintessence, Chicago 36-38
15. Migliorati C.A. Bisphosphonates and oral cavity avascular bone necrosis. J Clin Oncol 21 (2003) 4253-4254
16. Ruggiero S.L., Mehrotha B., Rosenberg T.J., and Engroff S.L. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 62 (2004) 527-534
17. Bamias A., Kastritis E., Bamia C., Moulopoulos L.A., Melakopoulos I., Bozas G., et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 23 (2005) 8580-8587
18. Schirmer I., Peters H., Reichart P.A., and Dürkop H. Bisphosphonates and osteonecrosis of the jaw. Mund Kiefer Gesichtschir 9 (2005) 239-245 German
19. Abu-Id M.H., Açil Y., Gottschalk J., and Kreusch T. Bisphosphonate-associated osteonecrosis of the jaw. Mund Kiefer Gesichtschir 10 (2006) 73-81 German
20. Khosla S., Burr D., Cauley J., Dempster D.W., Ebeling P.R., Felsenberg D., et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 22 (2007) 1479
21. Allen M.R. Animal models of osteonecrosis of the jaw. J Musculoskeletal Neuronal Interact 7 (2007) 358-360
22. Assael L.A. The science of bisphosphonate-related osteonecrosis of the jaws: the thin white line. J Oral Maxillofac Surg 65 (2007) 1275-1276
23. Shane E., Goldring S., Christakos S., Drezner M., Eisman J., Silverman S., et al. Osteonecrosis of the jaw: more research needed. J Bone Miner Res 21 (2006) 1503-1505
24. National Institutes of Health Program Announcement. Bisphosphonate-associated osteonecrosis of the jaw: pathophysiology and epidemiology (2006). http://www.nidcr.nih.gov/Funding/CurrentFundingOpportunities/recentlyCleared/
25. In: Marx R.E. (Ed). Risks, prevention, and management of oral bisphosphonate-induced osteonecrosis. In: Oral and intravenous bisphosphonate-induced osteonecrosis of the jaws: history, etiology, prevention, and treatment (2007), Quintessence Publishing, Hanover Park, IL 84
26. Allen M.R., and Burr D.B. Mandible matrix necrosis in beagle dogs after 3 years of daily oral bisphophonate treatment. J Oral Maxillofac Surg 66 (2008) 987-994
27. Sonis S.T., Watkins B.A., Lyng G.D., Lerman M.A., and Anderson K.C. Bony changes in the jaws of rats treated with zolendronic acid and dexamethasone before dental extractions mimic bisphosphonate-related osteonecrosis in cancer patients. Oral Oncol 45 (2009) 164-172
28. Pytlik M., Kaczmarczyk-Sedlak I., Sliwiński L., Janiec W., and Rymkiewicz I. Effect of concurrent administration of alendronate sodium and retinol on development of changes in histomorphometric parameters of bones induced by ovariectomy in rats. Pol J Pharmacol 56 (2004) 571-579
29. Kaczmarczyk-Sedlak I., and Janiec W. Effects of catecholamines on blood pressure in the long bone marrow cavity in rats with bisphosphonate-induced osteopetrosis. Pharmacol Rep 57 (2005) 623-634
30. Kapitola J., Zák J., Lacinová Z., and Justová V. Effect of growth hormone and pamidronate on bone blood flow, bone mineral and IGF-I levels in the rat. Physiol Res 49 (2000) S101-S106
31. Kolota G. Drug for bones is newly linked to jaw disease (2006), The New York Times, New York. http://www.nytimes.com/2006/06/02/health/02jaw.html?hp&ex=1149307200&en=add01a0366c2bcf3&ei=5094&partner=homepage Accessed June 2, 2006
32. Greenberg M.S. Intravenous bisphosphonates and osteonecrosis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 98 (2004) 259-260
33. Badros A., Weikel D., Salama A., Goloubeva O., Schneider A., Rapoport A., et al. Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. J Clin Oncol 24 (2006) 945
34. Hoff A.O., Toth B.B., and Altundag K. Osteonecrosis of the jaw in patients receiving intravenous bisphosphonate therapy. J Clin Oncol 2006 ASCO Annual Meeting Proceedings (postmeeting addition) 24 (2006) 8528. htpp://meeting.jco.org/cgi/content/abstract/24/18_suppl/8528 Accessed June 20, 2006
35. Marx R.E. Modes of action and pharmacokinetics of the bisphosphonate family. Oral and intravenous bisphosphonate-induced osteonecrosis of the jaws: history, etiology, prevention, and treatment (2007), Quintessence Publishing, Hanover Park, IL 11-15
36. Martin T.J., and Grin V. Bisphosphonates-mechanisms of action. Australian Prescriber 23 (2000) 130-132
37. Allauddin S., Alan G.T., and Sobia Z. Bisphosphonate-induced osteonecrosis of the jaw:a medical enigma?. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 108 (2009) e1-e8
38. Sparidans R.W., Twiss I.M., and Talbot S. Bisphosphonates in bone diseases. Pharm World Sci 20 (1998) 206-213
39. Shipman C.M., Rogers M.J., Apperley J.F., Russell R.G., and Croucher P.L. Bisphosphonates induces apoptosis in human myeloma cell lines: a novel anti-tumor activity. Br J Haematol 98 (1997) 665-672
40. Van Beek E.R., Cohen L.H., Leroy I.M., Ebetino F.H., Lowik C.W., and Papapoulos S.E. Diferentiating the mechanisms of antiresorptive action of nitrogen containing bisphosphonates. Bone 33 (2003) 805-811
41. Kapitola J., and Zak J. Effect of pamidronate on bone blood flow in oophorectomized rats. Physiol Res 47 (1998) 237-240
42. Marx R.E. Modes of action and pharmacokinetics of the bisphosphonate family. Oral and intravenous bisphosphonate-induced osteonecrosis of the jaws: history, etiology, prevention, and treatment (2007), Quintessence Publishing, Hanover Park, IL 15-17
43. Bauss F., Pfister T., and Pappapoulos S. Ibandronate uptake in the jaw is similar to long bones and vertebrae in the rat. J Bone Miner Metab 26 (2008) 406-408
44. Reid I.R., Bolland M.J., and Grey A.B. Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity?. Bone 41 (2007) 318-320
45. Boonyapakorn T., Schirmer I., Reichart P.A., Sturm I., and Massenkeil G. Bisphosphonate-induced osteonecrosis of the jaws: prospective study of 80 patients with multiple myeloma and other malignancies. Oral Oncol 44 (2008) 857-869
46. Burr D.B., and Allen M.R. Mandibular necrosis in beagle dogs treated with bisphosphonates. Orthod Craniofac Res 12 (2009) 221-228
47. Migliorati C.A., Schubert M.M., Peterson D.E., and Seneda L.M. Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy. Cancer 104 (2005) 83
48. Lehrer S., Montazem A., Ramanathan L., Pessin-Minsley M., Pfail J., Stock R.G., et al. Bisphosphonate-induced osteonecrosis of the jaws, bone markers, and a hypothesized candidate gene. J Oral Maxillofac Surg 67 (2009) 159-6